{"id":51292,"date":"2026-08-05T00:05:00","date_gmt":"2026-08-04T22:05:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=470fe03e7491ffbda45f1210b5be5149"},"modified":"2026-08-05T00:05:00","modified_gmt":"2026-08-04T22:05:00","slug":"deadline-approaching-capricor-therapeutics-inc-capr-shareholders-who-lost-money-urged-to-contact-law-offices-of-howard-g-smith","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=51292","title":{"rendered":"Deadline Approaching: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith"},"content":{"rendered":"

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 <\/b>deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Capricor Therapeutics, Inc. (\"Capricor\" or the \u201cCompany\u201d) (NASDAQ: CAPR<\/a>) securities between December 17, 2025 and July 26, 2026<\/b>, <\/b>inclusive (the \u201cClass Period\u201d).<\/p>

\nIF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR THERAPEUTICS, INC. (CAPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.<\/b><\/p>

\nContact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com<\/a>, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com<\/a>.<\/p>

\nWhat Happened?<\/b><\/p>

\nOn July 27, 2026, the US Food and Drug Administration released briefing documents ahead of its advisory committee meeting with Capricor regarding the Company's cell therapy for a heart condition related to Duchenne muscular dystrophy.<\/p>

\nAmong other things, the briefing documents take issue with the manner in which Capricor measured results after the therapy's late-stage trial ended, stating the \"FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified<\/i><\/b>, as it adds complexity and reduces accuracy.\" The briefing documents conclude that, among other things, \"the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.<\/i><\/b>\"<\/p>

\nCantor Fitzgerald analyst Kristen Kluska published an investor note on the issue, stating the FDA\u2019s \u201cbriefing documents paint an ugly picture<\/i><\/b>\u201d and \u201craise several concerns and make allegations about the integrity of data collecting<\/i><\/b>.\u201d<\/p>

\nOn this news, shares of Capricor stock declined as much as $12.29, or 62.39%, during intraday trading on July 27, 2026.<\/p>

\nOn July 29, 2026, the AdCom met to discuss the Deramiocel BLA. The next day, Medscape reported that the panel relied on SAP version 1.1 as the \u201cprespecified plan\u201d and, in a non-binding 9-3 vote, the panel \u201cconcluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy.\u201d<\/p>

\nOn this news, Capricor\u2019s stock fell $2.38, or 36%, to close at $4.19 per share on July 30, 2026, on unusually heavy trading volume.<\/p>

\nWhat Is the Lawsuit About?<\/b><\/p>

\nThroughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (2) that the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) that, as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) that, as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) that, as a result of the foregoing, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>

\nIf you purchased or otherwise acquired Capricor Therapeutics, Inc. securities between December 17, 2025 and July 26, 2026, you may move the Court no later than September 28, 2026 <\/b>to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements.<\/p>

\nContact Us to Participate or Learn More:<\/b><\/p>

\nIf you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:<\/p>

\nLaw Offices of Howard G. Smith\n3070 Bristol Pike, Suite 112\nBensalem, Pennsylvania 19020\nTelephone: (215) 638-4847\nEmail: howardsmith@howardsmithlaw.com<\/a>Visit our website at: www.howardsmithlaw.com<\/a>.<\/p>

\nTo be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.<\/p>

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

\nLaw Offices of Howard G. Smith\nHoward G. Smith, Esquire\n215-638-4847\nhowardsmith@howardsmithlaw.com<\/a>www.howardsmithlaw.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Capricor Therapeutics, Inc. (\u00ab\u00a0Capricor\u00a0\u00bb …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-51292","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51292"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51292\/revisions"}],"predecessor-version":[{"id":51293,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51292\/revisions\/51293"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}